Stifel Reiterates Hold Rating on Tandem Diabetes Care (TNDM), Warns the Increasingly Competitive Environment May Decelerate Growth
Tweet Send to a Friend
Stifel analyst Matthew Blackman reiterated a Hold rating and $122.00 price target on Tandem Diabetes Care (NASDAQ: TNDM), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
